Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
2,356
Views
26
CrossRef citations to date
0
Altmetric
Back Matter

Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies

Jacobo Rogadoa Medical Oncology Department, Instituto De Investigación Sanitaria La Princesa, HU La Princesa, Madrid, Spain;b Medical Oncology Department, HU Infanta Leonor, Madrid, SpainView further author information
,
Nuria Romero-Laordena Medical Oncology Department, Instituto De Investigación Sanitaria La Princesa, HU La Princesa, Madrid, SpainView further author information
,
José Miguel Sanchez-Torresa Medical Oncology Department, Instituto De Investigación Sanitaria La Princesa, HU La Princesa, Madrid, SpainView further author information
,
Ana María Ramos-Levic Endocrinology Department, Instituto De Investigación Sanitaria La Princesa, HU La Princesa, Madrid, SpainView further author information
,
Vilma Pacheco-Barciaa Medical Oncology Department, Instituto De Investigación Sanitaria La Princesa, HU La Princesa, Madrid, SpainView further author information
,
Ana Isabel Ballesterosa Medical Oncology Department, Instituto De Investigación Sanitaria La Princesa, HU La Princesa, Madrid, SpainView further author information
,
Reyes Arranzd Hematology Department, HU La Princesa, Madrid, SpainView further author information
,
Alicia Lorenzoe Hematology Department, Complejo Asistencial De Segovia, Segovia, Castilla Y León, SpainView further author information
,
Pedro Gullonf Social and Cardiovascular Epidemiology Research Group, Alcalá University, Madrid, SpainView further author information
,
Ana Garridoa Medical Oncology Department, Instituto De Investigación Sanitaria La Princesa, HU La Princesa, Madrid, SpainView further author information
,
José María Serra López-Matenciog Hospital Pharmacy Department, HU La Princesa, Madrid, SpainView further author information
,
Olga Donnaya Medical Oncology Department, Instituto De Investigación Sanitaria La Princesa, HU La Princesa, Madrid, SpainView further author information
,
Magdalena Adradosh Pathology Department, Instituto De Investigación Sanitaria La Princesa, HU La Princesa, Madrid, SpainView further author information
,
Pablo Costasa Medical Oncology Department, Instituto De Investigación Sanitaria La Princesa, HU La Princesa, Madrid, SpainView further author information
,
Javier Aspai Neumology Department, Instituto De Investigación Sanitaria La Princesa, HU La Princesa, Madrid, SpainView further author information
,
Arantzazu Alfrancaj Immunology Department, Instituto De Investigación Sanitaria La Princesa, Madrid, SpainView further author information
,
Rebeca Mondejara Medical Oncology Department, Instituto De Investigación Sanitaria La Princesa, HU La Princesa, Madrid, Spain;k Department of Medicine, Universidad Autónoma De Madrid, Madrid, SpainView further author information
&
Ramon Colomera Medical Oncology Department, Instituto De Investigación Sanitaria La Princesa, HU La Princesa, Madrid, Spain;k Department of Medicine, Universidad Autónoma De Madrid, Madrid, SpainCorrespondence[email protected]
View further author information
 show all
Article: 1751548 | Received 16 Nov 2019, Accepted 29 Feb 2020, Published online: 16 Apr 2020

Citations (26)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Catherine C. Fahey, Thomas J. Gracie & Douglas B. Johnson. (2023) Immune checkpoint inhibitors: maximizing benefit whilst minimizing toxicity. Expert Review of Anticancer Therapy 23:7, pages 673-683.
Read now
Yasaman Mojibi, Farhad Seif, Nastaran Mojibi, Azin Aghamajidi, Monireh Mohsenzadegan & Hamzeh-Ali Torang. (2022) Efficacy of immunotherapy in obese patients with cancer. Immunopharmacology and Immunotoxicology 44:4, pages 471-483.
Read now
Cynthia Yeung, Adi Kartolo, Ryan Holstead, Gordon Taylor Moffat, Lilian Hanna, Wilma Hopman & Tara Baetz. (2022) No Association Between BMI and Immunotoxicity or Clinical Outcomes for Immune Checkpoint Inhibitors. Immunotherapy 14:10, pages 765-776.
Read now

Articles from other publishers (23)

Bushra Salman, Nameer M AlWard, Zamzam Al-Hashami, Hadil Al-Sharqi, Hasan Al-Sayegh & Ikram A Burney. (2023) The Prevalence and Patterns of Toxicity With Immune Checkpoint Inhibitors in Solid Tumors: A Real-World Experience From a Tertiary Care Center in Oman. Cureus.
Crossref
Jian Yang, Jialuo He, Yiting Feng & Ming Xiang. (2023) Obesity contributes to hepatocellular carcinoma development via immunosuppressive microenvironment remodeling. Frontiers in Immunology 14.
Crossref
Ngozi D Akingbesote, Dennis Owusu, Ryan Liu, Brenda Cartmel, Leah M Ferrucci, Michelle Zupa, Maryam B Lustberg, Tara Sanft, Kim R M Blenman, Melinda L Irwin & Rachel J Perry. (2023) A review of the impact of energy balance on triple-negative breast cancer. JNCI Monographs 2023:61, pages 104-124.
Crossref
Paul Trinkner, Sophie Günther, Ina Monsef, Eva Kerschbaum, Michael von Bergwelt-Baildon, David M. Cordas dos Santos & Sebastian Theurich. (2023) Survival and immunotoxicities in association with sex-specific body composition patterns of cancer patients undergoing immune-checkpoint inhibitor therapy – A systematic review and meta-analysis. European Journal of Cancer 184, pages 151-171.
Crossref
Hiroki Ishihara, Yudai Ishiyama, Yuki Nemoto, Kazutaka Nakamura, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Hirohito Kobayashi, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Kazunari Tanabe, Tsunenori Kondo & Toshio Takagi. (2023) Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors. Clinical Genitourinary Cancer 21:1, pages 136-145.
Crossref
Xinyi Zhang, Mengyu Rui, Chao Lin, Zhi Li, Dongliang Wei, Ruxue Han, Houyu Ju & Guoxin Ren. (2022) The association between body mass index and efficacy of pembrolizumab as second‐line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer Medicine 12:3, pages 2702-2712.
Crossref
Guang-Tan Lin, Jiao-Bao Huang, Ju-Li Lin, Jian-Xian Lin, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Chao-Hui Zheng, Chang-Ming Huang & Ping Li. (2022) Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer. Frontiers in Immunology 13.
Crossref
José Antônio Fagundes Assumpção, Gabriel Pasquarelli-do-Nascimento, Mariana Saldanha Viegas Duarte, Martín Hernan Bonamino & Kelly Grace Magalhães. (2022) The ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy. Journal of Biomedical Science 29:1.
Crossref
Jacobo Rogado, Fernando Pozo, Kevin Troulé, José Miguel Sánchez-Torres, Nuria Romero-Laorden, Rebeca Mondejar, Olga Donnay, Anabel Ballesteros, Vilma Pacheco-Barcia, Javier Aspa, Fátima Al-Shahrour, Arantzazu Alfranca & Ramon Colomer. (2022) Excess weight and anti-PD-1 immune checkpoint inhibitor’s outcomes in non-small cell lung cancer. Clinical and Translational Oncology 24:11, pages 2241-2249.
Crossref
Ishani Joshi, Monica Peravali, Xue Geng, Suman Rao, Kevin Y. Chen, Irina Veytsman, Giuseppe Giaccone, Stephen V. Liu & Chul Kim. (2022) Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based Therapy. Clinical Lung Cancer 23:5, pages 438-445.
Crossref
Ana Cardeña-Gutiérrez & Mónica López Barahona. (2022) Predictive Biomarkers of Severe Immune-Related Adverse Events With Immune Checkpoint Inhibitors: Prevention, Underlying Causes, Intensity, and Consequences. Frontiers in Medicine 9.
Crossref
Jacobo Rogado, Fernando Pozo, Kevin Troule, José Miguel Sánchez-Torres, Nuria Romero-Laorden, Rebeca Mondejar, Olga Donnay, Anabel Ballesteros, Vilma Pacheco-Barcia, Javier Aspa, Fátima Al-Shahrour, Arantzazu Alfranca & Ramon Colomer. (2022) Peripheral Blood Mononuclear Cells Predict Therapeutic Efficacy of Immunotherapy in NSCLC. Cancers 14:12, pages 2898.
Crossref
Yiqing Huang, Yu Yang Soon, Folefac Aminkeng, Sen Hee Tay, Yvonne Ang, Adrian C. L. Kee, Boon Cher Goh, Alvin S. C. Wong & Ross A. Soo. (2021) Risk factors for immune‐related adverse events from anti‐PD ‐1 or anti‐ PD‐L1 treatment in an Asian cohort of nonsmall cell lung cancer patients . International Journal of Cancer 150:4, pages 636-644.
Crossref
Melissa L. Bastacky, Hong Wang, Dylan Fortman, Zahra Rahman, Gerard P. Mascara, Timothy Brenner, Yana G. Najjar, Jason J. Luke, John M. Kirkwood, Hassane M. Zarour & Diwakar Davar. (2021) Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis. Frontiers in Oncology 11.
Crossref
Peter H. Goff, Rashmi Bhakuni, Thomas Pulliam, Jung Hyun Lee, Evan T. Hall & Paul Nghiem. (2021) Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. Cancers 13:14, pages 3415.
Crossref
Laetitia Collet, Lidia Delrieu, Amine Bouhamama, Hugo Crochet, Aurélie Swalduz, Alexandre Nerot, Timothée Marchal, Sylvie Chabaud & Pierre Etienne Heudel. (2021) Association between Body Mass Index and Survival Outcome in Metastatic Cancer Patients Treated by Immunotherapy: Analysis of a French Retrospective Cohort. Cancers 13:9, pages 2200.
Crossref
Aneesha Kulkarni & Laura W. Bowers. (2021) The role of immune dysfunction in obesity-associated cancer risk, progression, and metastasis. Cellular and Molecular Life Sciences 78:7, pages 3423-3442.
Crossref
Alice Indini, Erika Rijavec, Michele Ghidini, Gianluca Tomasello, Monica Cattaneo, Francesca Barbin, Claudia Bareggi, Barbara Galassi, Donatella Gambini & Francesco Grossi. (2021) Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review. International Journal of Molecular Sciences 22:5, pages 2628.
Crossref
Haizhu Chen, Daquan Wang, Qiaofeng Zhong, Yunxia Tao, Yu Zhou & Yuankai Shi. (2020) Pretreatment body mass index and clinical outcomes in cancer patients following immune checkpoint inhibitors: a systematic review and meta-analysis. Cancer Immunology, Immunotherapy 69:12, pages 2413-2424.
Crossref
Paul Johannet, Amelia Sawyers, Yingzhi Qian, Samuel Kozloff, Nicholas Gulati, Douglas Donnelly, Judy Zhong & Iman Osman. (2020) Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer. Journal for ImmunoTherapy of Cancer 8:2, pages e001674.
Crossref
Ravindra Pramod Deshpande, Sambad Sharma & Kounosuke Watabe. (2020) The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors. Cancers 12:10, pages 2983.
Crossref
Jingjing Fan, Xiangfeng Shen, Yishu Wang, Hong-Lan Zhou, Guolong Liu, Yu-Lin Li & Zhi-Xiang Xu. (2020) Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1. Biomedicine & Pharmacotherapy 130, pages 110621.
Crossref
Elisabet Cuyàs, Sara Verdura, Begoña Martin-Castillo, Tomás Alarcón, Ruth Lupu, Joaquim Bosch-Barrera & Javier A. Menendez. (2020) Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. Cancers 12:7, pages 1757.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.